Personalised Cancer Vaccine Shows Promise in Cutting Melanoma Recurrence

A personalized cancer vaccine, developed using the same mRNA technology found in some COVID-19 vaccines, has demonstrated a significant reduction in the risk of melanoma returning or spreading in patients after surgery. In a major clinical trial involving over 1,100 participants, the experimental vaccine, when administered alongside the established immunotherapy drug Keytruda, cut the risk of disease recurrence or death by 42% over two years.

The trial also showed a 38% reduction in the risk of melanoma spreading across the body within the same timeframe. Researchers involved in the study suggest these findings could represent a pivotal moment in cancer treatment, moving personalized medicine closer to widespread application.

Personalized Approach

The treatment targets patients who have had their tumors surgically removed. In the trial, 1,137 adults received Keytruda, a drug that helps the immune system identify and fight cancer cells. Approximately two-thirds of these patients also received Intismeran, the experimental personalized vaccine, while the remaining participants were given a placebo.

Intismeran is tailored to each individual by analyzing their tumor's genetic makeup. This information is used to train the patient's immune system to recognize and attack any returning cancer cells. Professor Pippa Corrie, a consultant medical oncologist involved in the study, described the personalized approach as an exciting advancement and a "fabulous technology" that offers a "first proof of principle."

One trial participant, 75-year-old Tony Chapman, was diagnosed with melanoma in 2019. After surgery to remove his initial tumor, he discovered the cancer had spread to his lymph nodes. He volunteered for the study, not knowing if he received the vaccine or a placebo. Three years later, he remains cancer-free, undergoing regular check-ups.

Future Prospects

Drug manufacturers MSD and Moderna have reported positive results from earlier stages of testing, and their shares saw an increase following initial announcements. However, some financial analysts noted that the latest results were not as strong as those from a smaller, earlier trial, leading to a dip in stock prices.

Both companies have indicated they are in discussions with regulatory authorities, potentially paving the way for approval applications as early as next year. The widespread adoption of such a treatment in public health systems like the NHS would also depend on cost-effectiveness, considering the need for individual genetic analysis and custom vaccine production for each patient.

Further monitoring of trial participants will continue to assess the long-term impact on survival rates and the potential for cancer recurrence over extended periods. Independent experts have hailed the results as "very impressive" and an "important proof of principle for the field," while also cautioning that more extensive follow-up studies are necessary to fully understand the treatment's overall impact on patient longevity and its applicability across different cancer types.